- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07296484
Étude contre le diabète de type 2 intratable (CAPTAIN-T2D) (CAPTAIN-T2D)
Essai de Phase 2 du Clofutribène et du Placebo contre le Diabète de Type 2 Intratable (CAPTAIN-T2D)
CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
CAPTAIN-T2D is a two-part, multicenter, randomized, double-blind, parallel group, placebo- controlled trial of the 11-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor clofutriben. The primary objectives of this trial are to characterize the relationship of clofutriben dose to improved glycemic control, and to identify one or more doses suitable for Phase 3 evaluation, in patients with T2D and elevated cortisol.
The trial consists of two parts.
Part 1 (Screening) will last between approximately 5 to 9 weeks for most participants. The screening period duration allows for (sequentially) initial eligibility screen, dexamethasone suppression test, and further eligibility assessments.
During Part 2 (Treatment), participants will be randomized to placebo or one of four clofutriben doses. Part 2 will last 24 weeks with a follow-up phone call 4 weeks after the last dose of trial medication.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Arizona
-
Chandler, Arizona, États-Unis, 85225
- Recrutement
- Arizona Clinical Trials - Pecos
-
Contact:
- Kamila Manager
- Numéro de téléphone: 480-470-4000
- E-mail: kojeda@azclinicaltrials.com
-
Tucson, Arizona, États-Unis, 85711
- Recrutement
- Arizona Clinical Trials - Broadway
-
Contact:
- Leanne Manager
- Numéro de téléphone: 480-470-4000
- E-mail: lbuchenholz@azclinicaltrials.com
-
-
California
-
Fountain Valley, California, États-Unis, 92708
- Recrutement
- Ark Clinical Research - Fountain Valley
-
Contact:
- Lizeth Manager
- Numéro de téléphone: 323-588-1990
- E-mail: lsuncin@velocityclinical.com
-
Huntington Park, California, États-Unis, 90255
- Recrutement
- Velocity Clinical Research, Huntington Park
-
Contact:
- Tim Manager
- Numéro de téléphone: 5135799911
- E-mail: tpeterson@velocityclinical.com
-
La Mesa, California, États-Unis, 91942
- Recrutement
- Velocity Clinical Research - Gardena
-
Contact:
- Tim Manager
- Numéro de téléphone: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
Long Beach, California, États-Unis, 90815
- Recrutement
- Ark Clinical Research - Long Beach
-
Contact:
- Mike Manager
- Numéro de téléphone: 562-997-1000
- E-mail: mdelgado@arkclinicalresearch.com
-
Los Angeles, California, États-Unis, 90057
- Recrutement
- Velocity Clinical Research, Los Angeles
-
Contact:
- Tim Manager
- Numéro de téléphone: 5135799911
- E-mail: tpeterson@velocityclinical.com
-
Los Angeles, California, États-Unis, 90015
- Recrutement
- Los Angeles Institute for Metabolic Research
-
Contact:
- Lourdes Manager
- Numéro de téléphone: (213) 373-8380
- E-mail: lgaribay@metabolic.la
-
Northridge, California, États-Unis, 98433
- Recrutement
- Amicis Research Center- Nordhoff
-
Contact:
- Veronica Clinical Research Manager
- Numéro de téléphone: (818) 929-7774
- E-mail: veronica.macias@amicisresearch.com
-
San Diego, California, États-Unis, 92120
- Recrutement
- Alliance Clinical San Diego
-
Contact:
- Sandra Manager
- Numéro de téléphone: (858) 299-0009
- E-mail: SMisic@allianceclinicalnetwork.com
-
-
Florida
-
Edgewater, Florida, États-Unis, 32132
- Recrutement
- Velocity Clinical Research, New Smyrna Beach
-
Contact:
- Tim Manager
- Numéro de téléphone: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
Fort Lauderdale, Florida, États-Unis, 33312
- Recrutement
- The Center for Diabetes and Endocrine Care
-
Contact:
- Marie Study Coordinator
- Numéro de téléphone: ext 236 954-963-7191
- E-mail: mmartin@diabetes-endocare.com
-
Miami, Florida, États-Unis, 33173
- Recrutement
- Admed Research LLC
-
Contact:
- Indiana Manager
- Numéro de téléphone: 786-687-2882
- E-mail: igonzalez@admedresearch.com
-
New Port Richey, Florida, États-Unis, 34652
- Recrutement
- Suncoast Clinical Research, Inc
-
Contact:
- Cathy Manager
- Numéro de téléphone: 727-849-4131
- E-mail: cbarnes@suncoastclinicalresearch.com
-
Port Charlotte, Florida, États-Unis, 33952
- Recrutement
- Innovative Research Institute
-
Contact:
- Lauren Manager
- Numéro de téléphone: (+1) 2832276233
- E-mail: l.ellis@medpace.com
-
Port Orange, Florida, États-Unis, 32127
- Recrutement
- Progressive Medical Research
-
Contact:
- Nora Clinical Research Manager
- Numéro de téléphone: 3457 386-304-7070
- E-mail: norab@progressivemedicalresearch.com
-
Winter Park, Florida, États-Unis, 32789
- Recrutement
- Conquest Research
-
Contact:
- Malisa Manager
- Numéro de téléphone: 407-916-0060
- E-mail: malisa.agard@conquestresearch.com
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30303
- Recrutement
- Emory University School of Medicine
-
Contact:
- Rohit Manager
- Numéro de téléphone: 404-778-1695
- E-mail: rohit.parab@emory.edu
-
Columbus, Georgia, États-Unis, 31904
- Recrutement
- IACT Health-Brookstone Centre Pkwy
-
Contact:
- kristina Manager
- Numéro de téléphone: 706.321.0495
- E-mail: kristina.erb@centricityresearch.com
-
-
Idaho
-
Boise, Idaho, États-Unis, 83709
- Recrutement
- Paradigm Clinical Research - Boise, ID
-
Contact:
- Janaie Manager
- Numéro de téléphone: 208-801-7440
- E-mail: jbounsana@paradigm-research.com
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60607
- Recrutement
- Chicago Clinical Research Institute
-
Contact:
- Manognya Clinical Research Manager
- Numéro de téléphone: 303 3127913241
- E-mail: manognya@ccrii.us
-
-
Iowa
-
West Des Moines, Iowa, États-Unis, 50226
- Recrutement
- Iowa Diabetes and Endocrinology Research Center
-
Contact:
- Crystal Manager
- Numéro de téléphone: 515-207-7486
- E-mail: choffman@iderc.com
-
-
Kansas
-
Wichita, Kansas, États-Unis, 67226
- Recrutement
- Alliance for Multispecialty Research - Wichita East
-
Contact:
- Terry Manager
- Numéro de téléphone: 316-689-6635
- E-mail: terry.klein@amr-clinical.com
-
-
Kentucky
-
Edgewood, Kentucky, États-Unis, 41017
- Recrutement
- St. Elizabeth Healthcare
-
Contact:
- Amber Manager
- Numéro de téléphone: 859-655-1567
- E-mail: amber.avery@stelizabeth.com
-
-
Louisiana
-
Lafayette, Louisiana, États-Unis, 70508
- Recrutement
- Velocity Clinical Research, Lafayette
-
Contact:
- Tim Manager
- Numéro de téléphone: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
Metairie, Louisiana, États-Unis, 70006
- Recrutement
- NOLA Care Clinical Research
-
Contact:
- Rosina Manager
- Numéro de téléphone: 504-427-6324
- E-mail: rosinaducote@gmail.com
-
New Orleans, Louisiana, États-Unis, 70112
- Recrutement
- Tulane University School of Medicine
-
Contact:
- Neha Manager
- Numéro de téléphone: 5049889803
- E-mail: nupadhyay@tulane.edu
-
-
Maryland
-
Rockville, Maryland, États-Unis, 20854
- Recrutement
- Velocity Clinical Research, Rockville
-
Contact:
- Tim Manager
- Numéro de téléphone: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
-
Massachusetts
-
Springfield, Massachusetts, États-Unis, 011030
- Recrutement
- Elixia SISU BHR - Springfield
-
Contact:
- Darlene Manager
- Numéro de téléphone: 5617970336
- E-mail: darlene.djaba@empathxresearch.com
-
-
Michigan
-
Troy, Michigan, États-Unis, 48085
- Recrutement
- Oakland Medical Research Center
-
Contact:
- Juliejo (Julie) Clinical Research Manager
- Numéro de téléphone: 248-687-7412
- E-mail: juliejolafave@msn.com
-
-
Nebraska
-
Lincoln, Nebraska, États-Unis, 68510
- Recrutement
- Velocity Clinical Research, Lincoln
-
Contact:
- Tim Manager
- Numéro de téléphone: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
Omaha, Nebraska, États-Unis, 68134
- Recrutement
- Velocity Clinical Research, Omaha
-
Contact:
- Tim Manager
- Numéro de téléphone: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
-
Nevada
-
Las Vegas, Nevada, États-Unis, 89148
- Recrutement
- Palm Research Center, Inc.
-
Contact:
- Raffaela Manager
- Numéro de téléphone: 702-736-5161
- E-mail: raffaela@palmresearchcenter.com
-
Las Vegas, Nevada, États-Unis, 89108
- Recrutement
- Alliance Clinical - Las Vegas
-
Contact:
- Stephanie Manager
- Numéro de téléphone: (702) 680-1500
- E-mail: sruvalcaba@allianceclinicalnetwork.com
-
-
New York
-
Albany, New York, États-Unis, 12203
- Recrutement
- Albany Medical College
-
Contact:
- Mohammed Manager
- Numéro de téléphone: 518-264-4462
- E-mail: ismailmoh@amc.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27514
- Recrutement
- University of North Carolina at Chapel Hill
-
Contact:
- Jessica Manager
- Numéro de téléphone: 984-974-3004
- E-mail: jessica_caffey@med.unc.edu
-
Greenville, North Carolina, États-Unis, 27834
- Recrutement
- Physicians East
-
Contact:
- Kristen Manager
- Numéro de téléphone: 252-413-6392
- E-mail: ktaylor@physicianseast.com
-
Morehead City, North Carolina, États-Unis, 28557
- Recrutement
- Lucas Research Inc
-
Contact:
- Christina Manager
- Numéro de téléphone: 252-222-5700
- E-mail: christina.tornes@centricityresearch.com
-
Wilmington, North Carolina, États-Unis, 28401
- Recrutement
- PMG Research of Wilmington, LLC
-
Contact:
- Kevin Manager
- Numéro de téléphone: 910.815.6108
- E-mail: cannon1099@me.com
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45219
- Recrutement
- Velocity Clinical Research, Cincinnati, Mt. Auburn
-
Contact:
- Tim Manager
- Numéro de téléphone: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
Cincinnati, Ohio, États-Unis, 45242
- Recrutement
- Velocity Clinical Research - Cincinnati, Blue Ash
-
Contact:
- Tim Manager
- Numéro de téléphone: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
Columbus, Ohio, États-Unis, 43201
- Recrutement
- Endocrinology Associates, Inc
-
Contact:
- Edward Clinical Research Manager
- Numéro de téléphone: 614-453-9999
- E-mail: ek@endocrinology-associates.com
-
Columbus, Ohio, États-Unis, 43215
- Recrutement
- Remington Davis, Inc
-
Contact:
- Tsunami Clinical Research Manager
- Numéro de téléphone: 614-487-2560
- E-mail: Tbrisco@remdavis.com
-
-
Oregon
-
Eugene, Oregon, États-Unis, 97404
- Recrutement
- Willamette Valley Clinical Studies
-
Contact:
- Patricia Manager
- Numéro de téléphone: 541-461-0132
- E-mail: drpatb@aol.com
-
-
Pennsylvania
-
West Chester, Pennsylvania, États-Unis, 19380
- Recrutement
- Suburban Research Associates
-
Contact:
- Tom Manager
- Numéro de téléphone: 610-891-9024
- E-mail: tfrancis@suburbanresearch.com
-
-
South Carolina
-
Anderson, South Carolina, États-Unis, 29621
- Recrutement
- Velocity Clinical Research, Anderson
-
Contact:
- Tim Manager
- Numéro de téléphone: (864) 965-0190
- E-mail: tpeterson@velocityclinical.com
-
Mt. Pleasant, South Carolina, États-Unis, 29464
- Recrutement
- Accellacare Charleston
-
Contact:
- Dhruva Manager
- Numéro de téléphone: (843) 849-1880
- E-mail: dhruva.patel@accellacare.com
-
-
Texas
-
Austin, Texas, États-Unis, 78759
- Recrutement
- Velocity Clinical Research, Austin
-
Contact:
- Tim Manager
- Numéro de téléphone: 513-673-4057
- E-mail: tpeterson@velocityclinical.com
-
Dallas, Texas, États-Unis, 75230
- Recrutement
- Velocity Clinical Research - Dallas
-
Contact:
- Tim Manager
- Numéro de téléphone: (972) 566-8631
- E-mail: tpeterson@velocityclinical.com
-
Houston, Texas, États-Unis, 77040
- Recrutement
- Juno Research, LLC
-
Contact:
- Lian manager
- Numéro de téléphone: 713-779-5494
- E-mail: lian_ramos@junoresearch.us
-
Lampasas, Texas, États-Unis, 76550
- Recrutement
- Radiance Clinical Research
-
Contact:
- Lauren Clinical Research Manager
- Numéro de téléphone: 512-556-4130
- E-mail: lgarner@radianceclinical.com
-
Lewisville, Texas, États-Unis, 75057
- Recrutement
- Alliance Clinical - Lewisville (Epic Clinical Research)
-
Contact:
- Jessica Manager
- Numéro de téléphone: (469) 361-8007
- E-mail: jpowell@allianceclinicalnetwork.com
-
Mission, Texas, États-Unis, 78572
- Recrutement
- Texas Valley Clinical Research - Mission, TX
-
Contact:
- Omar Manager
- Numéro de téléphone: 9568887400
- E-mail: gonzalez.md@tvcrmission.com
-
Round Rock, Texas, États-Unis, 78681
- Recrutement
- Texas Diabetes & Endocrinology, P.A. - Round Rock
-
Contact:
- Olivia Clinical Research Manager
- Numéro de téléphone: 512-334-3505
- E-mail: knutty@tderesearch.com
-
San Antonio, Texas, États-Unis, 78229
- Recrutement
- Diabetes & Glandular Disease Clinic, P.A.
-
Contact:
- Myriam Manager
- Numéro de téléphone: 1532 210-614-8612
- E-mail: myriam.turner@dgdclinic.com
-
San Antonio, Texas, États-Unis, 78251
- Recrutement
- Texas Valley Clinical Research - San Antonio TX
-
Contact:
- Diana Manager
- Numéro de téléphone: 2105431990
- E-mail: diana@tvcrtrials.com
-
Seabrook, Texas, États-Unis, 77586
- Recrutement
- Elevate Clinical Research
-
Contact:
- Olga Clinical Research Manager
- Numéro de téléphone: 832-271-1598
- E-mail: olga.konshina@elevateclinical.com
-
Weslaco, Texas, États-Unis, 78596
- Recrutement
- Texas Valley Clinical Research, LLC
-
Contact:
- Czarina Manager
- Numéro de téléphone: 956-431-8090
- E-mail: czarina@tvcrtrials.com
-
-
Utah
-
West Jordan, Utah, États-Unis, 84088
- Recrutement
- Velocity Clinical Research, Salt Lake City
-
Contact:
- Tim Clinical Research Manager
- Numéro de téléphone: 5135799911
- E-mail: tpeterson@velocityclinical.com
-
-
Virginia
-
Suffolk, Virginia, États-Unis, 23435
- Recrutement
- Velocity Clinical Research, Suffolk
-
Contact:
- Tim Manager
- Numéro de téléphone: (757) 996-4200
- E-mail: tpeterson@velocityclinical.com
-
Vienna, Virginia, États-Unis, 22182
- Recrutement
- Conquest Research
-
Contact:
- Henry Manager
- Numéro de téléphone: 703-372-3268
- E-mail: Henry.Tran@conquestresearch.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
From Screening 1
-
Age at least 18 years.
-
HbA1c ≥7.5% documented within 3 months prior to Screening 1. (The historical HbA1c value must have been obtained after at least 2 months on the current [as of Screening 1] regimen).
-
Treatment with stable and adequate doses of ≥2 injectable or oral ADMs. (An ADM will be deemed stable if the dose has been the same for at least 3 months prior to Screening 1 and without change between Screening 1 and Day 1) (An ADM dose will be deemed adequate if it is at or above the maximal labelled dose, or a sub-maximal, but not starting, dose if limited by tolerability (confer with MM if less than half-maximal dose).
-
Adequate total daily insulin is defined as at least 0.3 units/kg/day. Insulin dose will be deemed stable with adjustments of up to 20% total daily dose during the 3 months prior to Screening 1 or between Screening 1 and Day 1.
-
Use of insulin pumps or insulin brand changes (e.g., due to insurance change or shortage) are to be discussed with the MM.
-
At least one of the following
- ≥3 stable and adequate ADMs;
- diabetes complication (retinopathy, nephropathy, neuropathy, atherosclerotic heart disease);
- hypertension requiring ≥2 adequately dosed AHMs;
- adequately dosed basal or basal plus prandial insulin in addition to at least 1 other ADM; and
- adequately dosed incretin agonist (a single or combination agent counts as one ADM) in addition to at least 1 other ADM;
- evidence or history of osteoporosis or non-traumatic fracture (e.g., vertebral body compression);
- or established diagnosis of a neoplastic (non-malignant) source of hypercortisolism and have failed, are ineligible for, or declined surgery.
-
At DST • Post-DST cortisol level >1.8 µg/dL and serum dexamethasone ≥140 ng/dL. Patients with an established diagnosis of neoplastic hypercortisolism do not require a DST.
At Screening 2
- HbA1c ≥7.5% at Screening 2. At Day 1
- No change in, or initiation of, medications for hypertension within 1 month prior to Day 1.
Exclusion Criteria:
-
New-onset diabetes (onset <1 year in the past).
-
Unwillingness to maintain with current glucose-lowering regimen during the trial.
-
Unwillingness to adjust, add, replace, or discontinue current or other glucose-lowering medications during the trial as directed by the investigator.
-
Unwillingness to comply with CGM or other trial procedures.
-
Investigator considers the patient will otherwise be unwilling or unable to complete the trial.
-
Night-shift worker or otherwise habitually awake from 23:00 to 07:00 h.
-
Evidence for significant hypoglycemia while on their current diabetic treatment regimen(This includes episodes of symptomatic Level 3 hypoglycemia requiring external assistance for recovery, or CGM-documented prolonged [>15 min] or repeated episodes of either Level 2 hypoglycemia leading to >1%, or Level 1 hypoglycemia leading to >4%, in "time below range" within 3 months prior to Screening 1 or between Screening 1 and Day 1).
-
Any of the following in medical history:
- Type 1 diabetes mellitus (T1D), latent autoimmune diabetes in adults (LADA), or familial forms of maturity-onset diabetes of the young (MODY);
- A hemoglobinopathy or other condition which may interfere with measurement of HbA1c (e.g., sickle cell disease HbSS or other variants HbEE thalassemia, hemolytic anemia, recent blood transfusion);
- Hypersensitivity or severe reaction to dexamethasone;
- Pheochromocytoma, or suspicion thereof;
- Anorexia, or other eating disorder;
- Glucocorticoid resistance;
- Multiple sclerosis;
- Significant hepatic impairment (e.g., Child-Pugh Class B or C);
- Idiopathic thrombocytopenic purpura;
- Untreated or inadequately controlled moderate-to-severe sleep apnea (apnea-hypopnea index ≥15). (Patients whose condition has been well controlled with Continuous Positive Airway Pressure (CPAP) use for at least 3 months prior to Screening 1 are not excluded. Patients with a STOP-BANG score 5-8 should be referred for a sleep study outside the trial and may rescreen if found not to have moderate-to-severe sleep apnea);
- Current alcohol consumption >14 units/week or >4 units in a single day for males, or >7 units/week or >3 units in a single day for females. (Patients with a CAGE score 2-4 should be evaluated further outside the trial and may be rescreened if found not to have an alcohol [or other substance] use disorder);
- Untreated or inadequately controlled major depressive disorder, generalized anxiety disorder, bipolar disorder, post-traumatic stress disorder, or schizophrenia.(Patients whose condition has been well controlled with stable medical therapy, or has been asymptomatic, for at least 3 months prior to Screening 1 are not excluded); or
- Any other medical condition (including malignancy) that is likely to interfere with trial assessments or the patient's ability to complete the trial.
- Any of the following in medication history:
- Any of the excluded medications listed in Section 6.9;
- Any investigational drug within 4 weeks or within less than five times the drug's half-life, whichever is longer, prior to Screening 1 or between Screening 1 and Day 1;
- Woman of childbearing potential (WOCBP) not willing to adhere to highly effective contraception or strict abstinence for the duration of the trial and for 90 days post completion/discontinuation; and
- Pregnancy (including a positive urine test) or current breast feeding.
From Screening 2
• Prior probability of undiagnosed endogenous Cushing syndrome based on either of:
- wo morning serum cortisol values after dexamethasone suppression >5.0 mcg/dL together with plasma dexamethasone >140 ng/mL; or
- a morning serum cortisol value after dexamethasone suppression >1.8 mcg/dL, together with plasma dexamethasone >140 ng/mL and any one of the following that is not attributable to an etiology other than endogenous Cushing's syndrome:
- supraclavicular/dorsocervical fat accumulation;
- irounding of the face (especially compared with prior photos);
- skin changes (violaceous striae, skin thinning, or excessive bruising);
- proximal muscle weakness on exam; or
- history of deep vein thrombosis/pulmonary embolism.
- Plans for, or medically unable to forego, treatment for endogenous Cushing syndrome or ACS within the next 8 months. (For clarity, patients with EnCS or ACS, not having such treatment plans, and medically able to forego treatment for 8 months may enroll if otherwise eligible).
- Severe, poorly controlled hypertension (mean systolic BP >160 mmHg or mean diastolic BP >100 mmHg) at Screening 2 or between Screening 2 and Day 1, including by at-home monitoring. (Such patients will be eligible to rescreen for Part 2 when they restore BP <160/100 mmHg for 1 month on a new stable medication regimen).
- Positive urine screen for recreational drugs (except tetrahydrocannabinol (THC)).
- Glomerular filtration rate (GFR) (determined using Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI]) <45 mL/min/1.73 m².
- Poorly controlled hyperthyroidism/hypothyroidism (confirmed by TSH or Free thyroxine [fT4]).
- Liver enzymes >3 × upper limit of normal (ULN) (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or bilirubin >1.5 × ULN.(excepting benign conditions such as Gilbert's)
- Known hypersensitivity to clofutriben or to any of the product
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Dose 1
clofutriben .2 mg oral tablet daily |
HSD-1 inhibitor
Autres noms:
|
|
Expérimental: Dose 2
clofutriben 2mg oral tablet daily |
HSD-1 inhibitor
Autres noms:
|
|
Expérimental: Dose 3
clofutriben 6mg oral tablet daily |
HSD-1 inhibitor
Autres noms:
|
|
Expérimental: Dose 4
clofutriben 12 mg oral tablet daily |
HSD-1 inhibitor
Autres noms:
|
|
Comparateur placebo: placebo
placebo control oral tablet daily |
Placebo |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of patients with both morning serum cortisol >1.8 mg/dL and morning plasma dexamethasone >=140 ng/dL (single composite endpoint) after a single dexamethasone 1 mg dose taken the prior night.
Délai: 8-10 hours after the dexamethasone 1 mg dose.
|
To assess prevalence in the trial population of morning cortisol non-suppression by a single dexamethasone 1 mg dose. |
8-10 hours after the dexamethasone 1 mg dose.
|
|
Glycated hemoglobin A1c (%) change from baseline to Week 24 by treatment.
Délai: 24 weeks.
|
To assess glycated hemoglobin A1c (%) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks. |
24 weeks.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Fasting plasma glucose (mmol/L) change from baseline to Week 24 by treatment.
Délai: 24 weeks
|
To assess glucose (mmol/L) changes, compared to placebo, in patients who receive each of 4 daily clofutriben doses for 24 weeks. |
24 weeks
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
To evaluate the safety of clofutriben in participants with T2D and EC.
Délai: From enrollment until end of trial 9 month
|
Frequency of TEAEs (treatment-emergent adverse even) by clofutriben dose |
From enrollment until end of trial 9 month
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du système endocrinien
- Tumeurs
- Maladies métaboliques
- Troubles du métabolisme du glucose
- Diabète sucré
- Syndromes paranéoplasiques
- Maladies des glandes surrénales
- Hyperfonction corticosurrénalienne
- Syndromes endocriniens paranéoplasiques
- Maladies nutritionnelles et métaboliques
- Diabète sucré, Type 2
- Syndrome de Cushing
- Syndrome d'ACTH, ectopique
- ASP3662
Autres numéros d'identification d'étude
- SPI-62-CL-2006
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .